Ivan Lowenthal MD
Participates in Phase II, III and IV pharmaceutical and cooperative group Oncology and Hematology clinical trials.
Research OrganizationsCancer Center, Yale
- A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer (CALGB 80702)
- S1310: Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer
- S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer